Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Research Report 2024(Status and Outlook)
Report Overview:
Non-alcoholic steatohepatitis (NASH) is a form of liver disease characterized by inflammation and liver cell damage caused by the accumulation of fat in the liver. It is often associated with obesity, insulin resistance, and metabolic syndrome. As there is currently no approved specific therapy for NASH, treatment primarily focuses on managing the underlying risk factors and minimizing liver damage.
The Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size was estimated at USD 1202.55 million in 2023 and is projected to reach USD 1764.60 million by 2029, exhibiting a CAGR of 6.60% during the forecast period.
This report provides a deep insight into the global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market in any manner.
Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Allergan plc
Pfizer Inc
Gilead Sciences
Genfit SA
Novartis AG
Intercepts Pharmaceuticals
Cadila Healthcare
Novo Nordisk
Raptor Pharmaceutical Corp
Galmed Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Conatus Pharmaceuticals
NGM Biopharmaceuticals
CymaBay Therapeutics
Boehringer Ingelheim
Eli Lilly and Company
Bristol Myers Squibb
Market Segmentation (by Type)
Imaging Techniques
Diagnostic Tests
Biopsy
Others
Market Segmentation (by Application)
Hospital Pharmacy
Online Channels
Retail Channels
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Non-alcoholic steatohepatitis (NASH) is a form of liver disease characterized by inflammation and liver cell damage caused by the accumulation of fat in the liver. It is often associated with obesity, insulin resistance, and metabolic syndrome. As there is currently no approved specific therapy for NASH, treatment primarily focuses on managing the underlying risk factors and minimizing liver damage.
The Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size was estimated at USD 1202.55 million in 2023 and is projected to reach USD 1764.60 million by 2029, exhibiting a CAGR of 6.60% during the forecast period.
This report provides a deep insight into the global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market in any manner.
Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Allergan plc
Pfizer Inc
Gilead Sciences
Genfit SA
Novartis AG
Intercepts Pharmaceuticals
Cadila Healthcare
Novo Nordisk
Raptor Pharmaceutical Corp
Galmed Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Conatus Pharmaceuticals
NGM Biopharmaceuticals
CymaBay Therapeutics
Boehringer Ingelheim
Eli Lilly and Company
Bristol Myers Squibb
Market Segmentation (by Type)
Imaging Techniques
Diagnostic Tests
Biopsy
Others
Market Segmentation (by Application)
Hospital Pharmacy
Online Channels
Retail Channels
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market
- Overview of the regional outlook of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
1.2 Key Market Segments
1.2.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Type
1.2.2 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Manufacturers (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites, Area Served, Product Type
3.6 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Competitive Situation and Trends
3.6.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS INDUSTRY CHAIN ANALYSIS
4.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
6.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Market Share by Type (2019-2024)
6.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price by Type (2019-2024)
7 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Sales by Application (2019-2024)
7.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
8 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY REGION
8.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Allergan plc
9.1.1 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.1.2 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.1.3 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.1.4 Allergan plc Business Overview
9.1.5 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
9.1.6 Allergan plc Recent Developments
9.2 Pfizer Inc
9.2.1 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.2.2 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.2.3 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.2.4 Pfizer Inc Business Overview
9.2.5 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
9.2.6 Pfizer Inc Recent Developments
9.3 Gilead Sciences
9.3.1 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.3.2 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.3.3 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.3.4 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
9.3.5 Gilead Sciences Business Overview
9.3.6 Gilead Sciences Recent Developments
9.4 Genfit SA
9.4.1 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.4.2 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.4.3 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.4.4 Genfit SA Business Overview
9.4.5 Genfit SA Recent Developments
9.5 Novartis AG
9.5.1 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.5.2 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.5.3 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.5.4 Novartis AG Business Overview
9.5.5 Novartis AG Recent Developments
9.6 Intercepts Pharmaceuticals
9.6.1 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.6.2 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.6.3 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.6.4 Intercepts Pharmaceuticals Business Overview
9.6.5 Intercepts Pharmaceuticals Recent Developments
9.7 Cadila Healthcare
9.7.1 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.7.2 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.7.3 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.7.4 Cadila Healthcare Business Overview
9.7.5 Cadila Healthcare Recent Developments
9.8 Novo Nordisk
9.8.1 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.8.2 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.8.3 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.8.4 Novo Nordisk Business Overview
9.8.5 Novo Nordisk Recent Developments
9.9 Raptor Pharmaceutical Corp
9.9.1 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.9.2 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.9.3 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.9.4 Raptor Pharmaceutical Corp Business Overview
9.9.5 Raptor Pharmaceutical Corp Recent Developments
9.10 Galmed Pharmaceuticals
9.10.1 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.10.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.10.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.10.4 Galmed Pharmaceuticals Business Overview
9.10.5 Galmed Pharmaceuticals Recent Developments
9.11 Madrigal Pharmaceuticals
9.11.1 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.11.2 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.11.3 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.11.4 Madrigal Pharmaceuticals Business Overview
9.11.5 Madrigal Pharmaceuticals Recent Developments
9.12 Viking Therapeutics
9.12.1 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.12.2 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.12.3 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.12.4 Viking Therapeutics Business Overview
9.12.5 Viking Therapeutics Recent Developments
9.13 Conatus Pharmaceuticals
9.13.1 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.13.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.13.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.13.4 Conatus Pharmaceuticals Business Overview
9.13.5 Conatus Pharmaceuticals Recent Developments
9.14 NGM Biopharmaceuticals
9.14.1 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.14.2 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.14.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.14.4 NGM Biopharmaceuticals Business Overview
9.14.5 NGM Biopharmaceuticals Recent Developments
9.15 CymaBay Therapeutics
9.15.1 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.15.2 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.15.3 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.15.4 CymaBay Therapeutics Business Overview
9.15.5 CymaBay Therapeutics Recent Developments
9.16 Boehringer Ingelheim
9.16.1 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.16.2 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.16.3 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.16.4 Boehringer Ingelheim Business Overview
9.16.5 Boehringer Ingelheim Recent Developments
9.17 Eli Lilly and Company
9.17.1 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.17.2 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.17.3 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.17.4 Eli Lilly and Company Business Overview
9.17.5 Eli Lilly and Company Recent Developments
9.18 Bristol Myers Squibb
9.18.1 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.18.2 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.18.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.18.4 Bristol Myers Squibb Business Overview
9.18.5 Bristol Myers Squibb Recent Developments
10 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST BY REGION
10.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast
10.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country
10.2.3 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region
10.2.4 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2030)
11.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2030)
11.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Application (2025-2030)
11.2.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application
11.2.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
1.2 Key Market Segments
1.2.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Type
1.2.2 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Manufacturers (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites, Area Served, Product Type
3.6 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Competitive Situation and Trends
3.6.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS INDUSTRY CHAIN ANALYSIS
4.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
6.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Market Share by Type (2019-2024)
6.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price by Type (2019-2024)
7 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Sales by Application (2019-2024)
7.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
8 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY REGION
8.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Allergan plc
9.1.1 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.1.2 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.1.3 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.1.4 Allergan plc Business Overview
9.1.5 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
9.1.6 Allergan plc Recent Developments
9.2 Pfizer Inc
9.2.1 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.2.2 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.2.3 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.2.4 Pfizer Inc Business Overview
9.2.5 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
9.2.6 Pfizer Inc Recent Developments
9.3 Gilead Sciences
9.3.1 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.3.2 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.3.3 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.3.4 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
9.3.5 Gilead Sciences Business Overview
9.3.6 Gilead Sciences Recent Developments
9.4 Genfit SA
9.4.1 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.4.2 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.4.3 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.4.4 Genfit SA Business Overview
9.4.5 Genfit SA Recent Developments
9.5 Novartis AG
9.5.1 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.5.2 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.5.3 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.5.4 Novartis AG Business Overview
9.5.5 Novartis AG Recent Developments
9.6 Intercepts Pharmaceuticals
9.6.1 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.6.2 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.6.3 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.6.4 Intercepts Pharmaceuticals Business Overview
9.6.5 Intercepts Pharmaceuticals Recent Developments
9.7 Cadila Healthcare
9.7.1 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.7.2 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.7.3 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.7.4 Cadila Healthcare Business Overview
9.7.5 Cadila Healthcare Recent Developments
9.8 Novo Nordisk
9.8.1 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.8.2 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.8.3 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.8.4 Novo Nordisk Business Overview
9.8.5 Novo Nordisk Recent Developments
9.9 Raptor Pharmaceutical Corp
9.9.1 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.9.2 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.9.3 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.9.4 Raptor Pharmaceutical Corp Business Overview
9.9.5 Raptor Pharmaceutical Corp Recent Developments
9.10 Galmed Pharmaceuticals
9.10.1 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.10.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.10.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.10.4 Galmed Pharmaceuticals Business Overview
9.10.5 Galmed Pharmaceuticals Recent Developments
9.11 Madrigal Pharmaceuticals
9.11.1 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.11.2 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.11.3 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.11.4 Madrigal Pharmaceuticals Business Overview
9.11.5 Madrigal Pharmaceuticals Recent Developments
9.12 Viking Therapeutics
9.12.1 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.12.2 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.12.3 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.12.4 Viking Therapeutics Business Overview
9.12.5 Viking Therapeutics Recent Developments
9.13 Conatus Pharmaceuticals
9.13.1 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.13.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.13.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.13.4 Conatus Pharmaceuticals Business Overview
9.13.5 Conatus Pharmaceuticals Recent Developments
9.14 NGM Biopharmaceuticals
9.14.1 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.14.2 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.14.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.14.4 NGM Biopharmaceuticals Business Overview
9.14.5 NGM Biopharmaceuticals Recent Developments
9.15 CymaBay Therapeutics
9.15.1 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.15.2 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.15.3 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.15.4 CymaBay Therapeutics Business Overview
9.15.5 CymaBay Therapeutics Recent Developments
9.16 Boehringer Ingelheim
9.16.1 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.16.2 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.16.3 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.16.4 Boehringer Ingelheim Business Overview
9.16.5 Boehringer Ingelheim Recent Developments
9.17 Eli Lilly and Company
9.17.1 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.17.2 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.17.3 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.17.4 Eli Lilly and Company Business Overview
9.17.5 Eli Lilly and Company Recent Developments
9.18 Bristol Myers Squibb
9.18.1 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
9.18.2 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
9.18.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
9.18.4 Bristol Myers Squibb Business Overview
9.18.5 Bristol Myers Squibb Recent Developments
10 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST BY REGION
10.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast
10.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country
10.2.3 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region
10.2.4 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2030)
11.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2030)
11.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Application (2025-2030)
11.2.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application
11.2.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Comparison by Region (M USD)
Table 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics as of 2022)
Table 10. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites and Area Served
Table 12. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Type
Table 13. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Challenges
Table 22. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Type (K Units)
Table 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Type (M USD)
Table 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
Table 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Share by Type (2019-2024)
Table 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Application
Table 30. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Application
Table 31. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Table 33. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2024)
Table 35. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Table 38. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 43. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 44. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 45. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Allergan plc Business Overview
Table 47. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 48. Allergan plc Recent Developments
Table 49. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 50. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 51. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Pfizer Inc Business Overview
Table 53. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 54. Pfizer Inc Recent Developments
Table 55. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 56. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 57. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 59. Gilead Sciences Business Overview
Table 60. Gilead Sciences Recent Developments
Table 61. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 62. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 63. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Genfit SA Business Overview
Table 65. Genfit SA Recent Developments
Table 66. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 67. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 68. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Novartis AG Business Overview
Table 70. Novartis AG Recent Developments
Table 71. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 72. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 73. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Intercepts Pharmaceuticals Business Overview
Table 75. Intercepts Pharmaceuticals Recent Developments
Table 76. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 77. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 78. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Cadila Healthcare Business Overview
Table 80. Cadila Healthcare Recent Developments
Table 81. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 82. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 83. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Novo Nordisk Business Overview
Table 85. Novo Nordisk Recent Developments
Table 86. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 87. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 88. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Raptor Pharmaceutical Corp Business Overview
Table 90. Raptor Pharmaceutical Corp Recent Developments
Table 91. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 92. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 93. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Galmed Pharmaceuticals Business Overview
Table 95. Galmed Pharmaceuticals Recent Developments
Table 96. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 97. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 98. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Madrigal Pharmaceuticals Business Overview
Table 100. Madrigal Pharmaceuticals Recent Developments
Table 101. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 102. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 103. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Viking Therapeutics Business Overview
Table 105. Viking Therapeutics Recent Developments
Table 106. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 107. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 108. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Conatus Pharmaceuticals Business Overview
Table 110. Conatus Pharmaceuticals Recent Developments
Table 111. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 112. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 113. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. NGM Biopharmaceuticals Business Overview
Table 115. NGM Biopharmaceuticals Recent Developments
Table 116. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 117. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 118. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. CymaBay Therapeutics Business Overview
Table 120. CymaBay Therapeutics Recent Developments
Table 121. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 122. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 123. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Boehringer Ingelheim Business Overview
Table 125. Boehringer Ingelheim Recent Developments
Table 126. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 127. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 128. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Eli Lilly and Company Business Overview
Table 130. Eli Lilly and Company Recent Developments
Table 131. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 132. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 133. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Bristol Myers Squibb Business Overview
Table 135. Bristol Myers Squibb Recent Developments
Table 136. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 137. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 138. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 139. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 140. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 141. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 142. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 143. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 144. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 145. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 146. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Consumption Forecast by Country (2025-2030) & (Units)
Table 147. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 148. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Type (2025-2030) & (K Units)
Table 149. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030) & (M USD)
Table 150. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price Forecast by Type (2025-2030) & (USD/Unit)
Table 151. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application (2025-2030)
Table 152. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Comparison by Region (M USD)
Table 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics as of 2022)
Table 10. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites and Area Served
Table 12. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Type
Table 13. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Challenges
Table 22. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Type (K Units)
Table 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Type (M USD)
Table 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
Table 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Share by Type (2019-2024)
Table 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Application
Table 30. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Application
Table 31. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Table 33. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2024)
Table 35. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Table 38. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 43. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 44. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 45. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Allergan plc Business Overview
Table 47. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 48. Allergan plc Recent Developments
Table 49. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 50. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 51. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Pfizer Inc Business Overview
Table 53. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 54. Pfizer Inc Recent Developments
Table 55. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 56. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 57. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 59. Gilead Sciences Business Overview
Table 60. Gilead Sciences Recent Developments
Table 61. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 62. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 63. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Genfit SA Business Overview
Table 65. Genfit SA Recent Developments
Table 66. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 67. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 68. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Novartis AG Business Overview
Table 70. Novartis AG Recent Developments
Table 71. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 72. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 73. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Intercepts Pharmaceuticals Business Overview
Table 75. Intercepts Pharmaceuticals Recent Developments
Table 76. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 77. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 78. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Cadila Healthcare Business Overview
Table 80. Cadila Healthcare Recent Developments
Table 81. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 82. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 83. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Novo Nordisk Business Overview
Table 85. Novo Nordisk Recent Developments
Table 86. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 87. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 88. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Raptor Pharmaceutical Corp Business Overview
Table 90. Raptor Pharmaceutical Corp Recent Developments
Table 91. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 92. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 93. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Galmed Pharmaceuticals Business Overview
Table 95. Galmed Pharmaceuticals Recent Developments
Table 96. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 97. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 98. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Madrigal Pharmaceuticals Business Overview
Table 100. Madrigal Pharmaceuticals Recent Developments
Table 101. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 102. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 103. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Viking Therapeutics Business Overview
Table 105. Viking Therapeutics Recent Developments
Table 106. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 107. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 108. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Conatus Pharmaceuticals Business Overview
Table 110. Conatus Pharmaceuticals Recent Developments
Table 111. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 112. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 113. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. NGM Biopharmaceuticals Business Overview
Table 115. NGM Biopharmaceuticals Recent Developments
Table 116. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 117. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 118. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. CymaBay Therapeutics Business Overview
Table 120. CymaBay Therapeutics Recent Developments
Table 121. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 122. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 123. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Boehringer Ingelheim Business Overview
Table 125. Boehringer Ingelheim Recent Developments
Table 126. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 127. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 128. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Eli Lilly and Company Business Overview
Table 130. Eli Lilly and Company Recent Developments
Table 131. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 132. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 133. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Bristol Myers Squibb Business Overview
Table 135. Bristol Myers Squibb Recent Developments
Table 136. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 137. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 138. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 139. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 140. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 141. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 142. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 143. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 144. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 145. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 146. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Consumption Forecast by Country (2025-2030) & (Units)
Table 147. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 148. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Type (2025-2030) & (K Units)
Table 149. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030) & (M USD)
Table 150. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price Forecast by Type (2025-2030) & (USD/Unit)
Table 151. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application (2025-2030)
Table 152. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD), 2019-2030
Figure 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) (2019-2030)
Figure 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Country (M USD)
Figure 11. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Share by Manufacturers in 2023
Figure 12. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers in 2023
Figure 13. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Type
Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2024)
Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023
Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application
Figure 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application in 2023
Figure 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2024)
Figure 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application in 2023
Figure 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 32. U.S. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 37. Germany Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 44. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 50. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 51. Brazil Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD), 2019-2030
Figure 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) (2019-2030)
Figure 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Country (M USD)
Figure 11. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Share by Manufacturers in 2023
Figure 12. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers in 2023
Figure 13. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Type
Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2024)
Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023
Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application
Figure 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application in 2023
Figure 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2024)
Figure 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application in 2023
Figure 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 32. U.S. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 37. Germany Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 44. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 50. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 51. Brazil Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Application (2025-2030)
